
Sandoz breaks ground on US$440m biosimilar facility in Slovenia
Sandoz, the former generics and biosimilars division of Novartis, has commenced construction on a new biosimilar manufacturing plant near Ljubljana, Slovenia, as part of a broader US$1.1bn investment in the country. The new facility, with a capital outlay …